AbbVie (ABBV)
(Delayed Data from NYSE)
$197.44 USD
-0.11 (-0.06%)
Updated Aug 26, 2024 04:00 PM ET
After-Market: $197.40 -0.04 (-0.02%) 6:18 PM ET
3-Hold of 5 3
C Value D Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$197.44 USD
-0.11 (-0.06%)
Updated Aug 26, 2024 04:00 PM ET
After-Market: $197.40 -0.04 (-0.02%) 6:18 PM ET
3-Hold of 5 3
C Value D Growth B Momentum D VGM
Zacks News
North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.
Pharma Stock Roundup: Lilly to Buy Loxo for $8B, M&A in Focus at JP Morgan Meet
by Zacks Equity Research
Lilly (LLY) is spending $8 billion to buy small cancer biotech Loxo Oncology. Big Pharma CEOs hint at spur in M&A activity in 2019.
Top Ranked Momentum Stocks to Buy for January 11th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 11th:
Top Ranked Momentum Stocks to Buy for January 10th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 10th:
Is AbbVie (ABBV) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
The Zacks Analyst Blog Highlights: Visa, Coca-Cola, AbbVie, Johnson & Johnson and Duke Energy
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Visa, Coca-Cola, AbbVie, Johnson & Johnson and Duke Energy
Novartis' Crizanlizumab Gets Breakthrough Therapy Status
by Zacks Equity Research
Novartis's (NVS) crizanlizumab gets Breakthrough Therapy designation by the FDA for the prevention of VOCs in patients of all genotypes with SCD.
Top Ranked Momentum Stocks to Buy for January 8th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, January 8th:
Top Analyst Reports for Visa, Coca-Cola & AbbVie
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Visa (V), Coca-Cola (KO) and AbbVie (ABBV).
AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $90.40 in the latest trading session, marking a +1.49% move from the prior day.
Neurocrine Gives Ingrezza Sales View, Updates on Pipeline
by Zacks Equity Research
Neurocrine (NBIX) issues preliminary sales outlook for Ingrezza with respect to the fourth quarter of 2018 as well as the full year. The company also lends an update on its pipeline.
Gilead (GILD) Collaborates With Yuhan for NASH Candidates
by Zacks Equity Research
Gilead (GILD) collaborates with Korean company Yuhan for the development of NASH treatments.
The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Merck, Pfizer and AbbVie
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Merck, Pfizer and AbbVie
AbbVie (ABBV) Inks Immunotherapy Deal with Private Biotech
by Zacks Equity Research
AbbVie (ABBV) inks deal with Tizona Therapeutics, to develop and commercialize CD39-targeted therapeutics, including TTX-030, which is a first-in-class antibody for the treatment of cancer.
Pharma Stock Roundup: BMY to Buy CELG for $74B, MRK Gets Rights to NASH Candidate
by Zacks Equity Research
Bristol-Myers (BMY) is spending $74 billion to buy Celgene. Merck (MRK) exercises option to gain rights to a NASH candidate from partner NGM Biopharmaceuticals.
Pfizer Begins Pivotal Study on Alopecia Areata Candidate
by Zacks Equity Research
Pfizer (PFE) initiates a pivotal phase IIb/III study to evaluate JAK3 inhibitor, PF-06651600, for treating moderate to severe alopecia areata.
Will Pfizer's (PFE) Stock Keep Up the Momentum in 2019?
by Zacks Equity Research
Pfizer (PFE) performs better than the industry in 2018 and looks well poised to keep the positive momentum alive in 2019.
AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, AbbVie (ABBV) closed at $92.19, marking a +1.17% move from the previous day.
Will AbbVie (ABBV) Shares Regain Lost Momentum in 2019?
by Zacks Equity Research
Though AbbVie's (ABBV) stock was down this year, it looks well poised for a recovery in 2019.
AbbVie Partners Lupin to Boost Hematological Cancer Pipeline
by Zacks Equity Research
AbbVie (ABBV) enters into partnership with India-based Lupin, gaining exclusive rights to develop and commercialize the latter's investigational MALT1 inhibitors for hematological cancers.
AbbVie (ABBV) Stock Moves -0.89%: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $84.16, moving -0.89% from the previous trading session.
AbbVie (ABBV) Seeks Approval for RA Candidate Upadacitinib
by Zacks Equity Research
AbbVie (ABBV) submits regulatory applications in the United States and EU for upadacitinib, for the treatment of adult patients with moderate to severe rheumatoid arthritis.
Gilead Partners with Scholar Rock for Fibrotic Disease Drugs
by Zacks Equity Research
Gilead Sciences (GILD) collaborates with Scholar Rock Holding Corporation for the development of fibrotic disease candidates.
Lilly's Taltz Outshines Humira in Psoriatic Arthritis Study
by Zacks Equity Research
Eli Lilly's (LLY) Taltz displays superiority over standard of care medicine Humira in a head-to-head study on patients with active psoriatic arthritis.
The Zacks Analyst Blog Highlights: McDonald???s, AbbVie, Altria, Wells Fargo and Disney
by Zacks Equity Research
The Zacks Analyst Blog Highlights: McDonald???s, AbbVie, Altria, Wells Fargo and Disney
AbbVie (ABBV) Stock Moves -0.79%: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $84.93 in the latest trading session, marking a -0.79% move from the prior day.